BioTuesdays
@BioTuesdays
Followers
812
Following
376
Media
243
Statuses
8K
Giving great healthcare companies and their stories as much exposure as we can. Subscribe to our newsletter. https://t.co/VE9jaNcNac
Joined September 2009
Stereotaxis has announced that it has submitted its robotically navigated catheter, EMAGIN 5F, for FDA regulatory clearance $STXS.
0
0
0
Personalis spotlights new publication from ICR and Royal Marsden on ctDNA testing in MRD $PSNL.
0
1
3
Medicus Pharma announced that its SKNJCT-003 Phase 2 study, evaluating the efficacy of two dose levels of D-MNA for the treatment of nodular basal cell carcinoma (BCC), has now randomized more than 50% of the 60 patients targeted for enrollment $MDCX.
0
0
0
Biodexa Pharmaceuticals has announced that eRapa, a form of rapamycin being developed for the treatment of familial adenomatous polyposis (FAP), has been granted Fast Track Designation by the FDA $BDRX.
0
0
1
Esko Bionics names National Seating & Mobility as exclusive distributor of Ekso Indego Personal device within the complex rehabilitation technology industry $EKSO.
0
0
0
New data from BioRestorative Therapies’ ongoing Phase 2 trial of cell-based BRTX-100 in cLDD potentially show disc microenvironment remodeling in addition to reported improvements in VAS and ODI $BRTX.
0
2
7
In our latest #BioTuesdays feature, CEO Melissa Sherman, Ph.D., shares how @MobilionSystems, is redefining analytical characterization with next-gen separation science.
0
1
0
Therma Bright has announced the appointment of Steve Raysely to its advisory board $TBRIF.
0
0
1
Tonix Pharmaceuticals has announced the appointment of Siobhan Fogarty as chief technical officer (CTO), effective immediately $TNXP.
0
0
1
INBS upgrades portable drug screening reader with multilingual capabilities $INBS.
0
0
0
HOOKIPA Pharma has announced the completion of enrollment for its Phase 1b trial evaluating HB-500 in patients with HIV $HOOK.
0
0
0
Tectonic Therapeutic has announced positive interim data from its Phase 1b acute hemodynamic clinical trial of TX45 in Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) $TECX.
0
0
0
Polyrizon has announced the filing of a patent application for its advanced intranasal drug delivery system Trap & Target (T&T) technology, with the Israel Patent Office (ILPO) $PLRZ.
0
0
0
NLS Pharmaceutics has announced the launch of a preclinical program to evaluate Mazindol ER as a novel treatment for fentanyl dependence $NLSP.
0
0
2
Conduit Pharmaceuticals has announced that the first phase in its collaboration with Sarborg, aimed at integrating advanced AI and cybernetics technology into its operations has been completed $CDT.
0
1
1
Stereotaxis has announced that it has received European CE Mark approval for its MAGIC ablation catheter, designed to perform cardiac ablation procedures aimed at treating heart arrhythmia $STXS.
0
0
0
RenovoRX highlights abstract showcasing promising PK data for TAMP in LAPC $RNXT.
0
0
0
Veru has announced positive topline results from its Phase 2b QUALITY clinical study evaluating the safety and efficacy of enobosarm in patients receiving WEGOVY (semaglutide) for weight reduction $VERU.
0
0
0
IPA (ImmunoPrecise Antibodies) has announced the development of a new class of GLP-1 therapies—leveraging AI—to enhance the efficacy, safety, and longevity of treatments for Type 2 diabetes (T2D) and obesity $IPA.
0
0
2
MeiraGTx has announced that its AAV8-RK-RetGC program for the treatment of patients with Leber congenital amaurosis due to GUCY2D mutations (LCA1) has been granted Rare Pediatric Disease Designation (RPDD) by the FDA $MGTX.
0
0
0